HC Wainwright Estimates Immuneering Q3 Earnings

Key Points

• HC Wainwright expects Immuneering to report a Q3 2026 loss of $0.31 per share and maintains a “Buy” rating with a $14 price target. Its full-year 2026 loss estimate is $1.10 per share.
• Analyst sentiment is mixed but leans positive: Immuneering has a consensus “Buy” rating and a $17.50 average price target, despite recent “Sell” ratings from Weiss Ratings and Wall Street Zen.
• Immuneering recently reported a Q2 loss of $0.27 per share, missing the $0.26 consensus estimate. The stock opened at $4.51, while institutional investors own 67.65% of outstanding shares.

Immuneering Corporation (NASDAQ:IMRX - Free Report) - Research analysts at HC Wainwright issued their Q3 2026 EPS estimates for Immuneering in a research report issued to clients and investors on Thursday, August 6th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of ($0.31) for the quarter. HC Wainwright has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for Immuneering's current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Immuneering's Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.10) EPS, FY2027 earnings at ($1.22) EPS, FY2028 earnings at ($1.30) EPS, FY2029 earnings at ($1.32) EPS and FY2030 earnings at ($0.40) EPS.

Several other equities research analysts also recently issued reports on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Immuneering in a report on Wednesday, June 24th. Wall Street Zen cut Immuneering from a "hold" rating to a "sell" rating in a report on Monday, July 20th. UBS Group set a $14.00 price objective on Immuneering in a research report on Thursday. Oppenheimer reissued an "outperform" rating on shares of Immuneering in a research note on Monday, June 1st. Finally, Cantor Fitzgerald began coverage on shares of Immuneering in a report on Wednesday, July 8th. They set an "overweight" rating and a $17.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $17.50.

Immuneering Stock Performance

Shares of Immuneering stock opened at $4.51 on Monday. The stock's fifty day simple moving average is $4.56 and its 200 day simple moving average is $4.98. The company has a market capitalization of $291.80 million, a PE ratio of -4.34 and a beta of 0.43. Immuneering has a 12 month low of $2.90 and a 12 month high of $10.08.

Immuneering (NASDAQ:IMRX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.01).

Institutional Trading of Immuneering

A number of institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in Immuneering by 2.0% during the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company's stock worth $776,000 after purchasing an additional 4,458 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Immuneering in the 4th quarter valued at $33,000. Southport Management L.L.C. lifted its position in Immuneering by 1.8% during the 4th quarter. Southport Management L.L.C. now owns 277,501 shares of the company's stock worth $1,826,000 after buying an additional 5,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Immuneering by 46.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company's stock worth $137,000 after buying an additional 6,196 shares in the last quarter. Finally, LPL Financial LLC boosted its stake in shares of Immuneering by 30.0% during the 4th quarter. LPL Financial LLC now owns 29,125 shares of the company's stock worth $192,000 after buying an additional 6,725 shares during the last quarter. 67.65% of the stock is currently owned by institutional investors.

Immuneering Company Profile

Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source